{"id":"W3100080748","doi":"10.1158/1078-0432.ccr-20-3305","title":"Entinostat plus Pembrolizumab in Patients with Metastatic NSCLC Previously Treated with Anti–PD-(L)1 Therapy","year":2020,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":124,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; National Institutes of Health; Bristol-Myers Squibb; AstraZeneca; York University; Syndax Pharmaceuticals; Memorial Sloan-Kettering Cancer Center; Genentech; Parker Institute for Cancer Immunotherapy; Damon Runyon Cancer Research Foundation; Roswell Park Cancer Institute","keywords":"Pembrolizumab; Medicine; Oncology; Internal medicine; Immunotherapy; Cancer","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008797169,0.0003855016,0.0010725,0.0001626153,0.0002505417,0.0003378767,0.0002194283,0.0003472333,0.0006012408],"category_scores_gemma":[0.0008125664,0.0001641864,0.0006131957,0.0002428188,0.0001874491,0.0003582991,0.0002533541,0.0007103484,0.0001350488],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006782244,"about_ca_system_score_gemma":0.0006736099,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008610302,"about_ca_topic_score_gemma":0.002725602,"domain_scores_codex":[0.9996916,0.0001102701,0.00002715421,0.00007154455,0.00004836534,0.00005106835],"domain_scores_gemma":[0.9995598,0.00008587701,0.0001055666,0.00002695162,0.0000252892,0.0001964592],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.2552434,0.01022816,0.4307732,0.0009818003,0.002798631,0.003208006,0.0006260298,0.00514487,0.05758788,0.0002412622,0.004444823,0.2287219],"study_design_scores_gemma":[0.03075479,0.1616215,0.7847109,0.0001531437,0.001431148,0.003663541,0.0001646495,0.006011565,0.005141489,0.0001655258,0.006129571,0.0000520848],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9983205,0.0009500949,0.00005532478,0.00008830713,0.00001225654,0.00005372217,0.00009550745,0.000005500641,0.0004187937],"genre_scores_gemma":[0.9986386,0.0004471864,0.0001603093,0.000145709,0.00003370188,0.00004271863,0.0003660271,0.000001681471,0.0001642228],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0010725,"threshold_uncertainty_score":0.0049209,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1847118665902934,"score_gpt":0.4600124273515743,"score_spread":0.2753005607612809,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}